Pep2Tango Therapeutics, a Potomac, MD-based startup centered on weight reduction therapies, obtained an funding from Versant Ventures.
The quantity of the deal was not disclosed.
The corporate intends to make use of the funds to develop its novel unimolecular tetra-receptor agonist peptides to deal with weight problems and associated situations.
Led by President, CEO and Chairperson Cristina Rondinone, Ph.D., and CSO Soumitra Ghosh, Ph.D., Pep2Tango Therapeutics is a biotechnology firm aiming to develop new peptide medicine that concentrate on unmet medical wants, together with for metabolic, endocrine, CNS and cardiovascular problems. Its novel drug growth strategy for weight problems focuses on unimolecular peptides that concentrate on a number of receptors, permitting for weight reduction efficacy, muscle mass preservation, improved tolerability, and streamlined growth and manufacturability.
The corporate is targeted on CMC growth actions to scale up drug candidate manufacturing and on operating IND-enabling research for a fast transition to first-in-human scientific research. An IND submission is anticipated in 2025.
Dr. Rondinone beforehand was president of Cellarity, and SVP and head of cardiovascular, renal and metabolic illnesses at AstraZeneca plc. Previous to that, she held roles of accelerating accountability in cardio-metabolic illness analysis and growth at MedImmune Inc., Roche and Abbott Laboratories, the place she led the analysis and growth of a number of molecules that moved to scientific trials together with Rezdiffra™, dorzagliatin and bentracimab.
Dr. Ghosh is a co-founder of a number of biotech corporations and served as government director for analysis at Amylin Prescribed drugs Inc., the place he was concerned in growth efforts culminating within the approvals of Byetta®, Symlin®, Bydureon® and Myalept®. Dr. Ghosh additionally served as president of the Peptide Therapeutics Basis.
FinSMEs
22/11/2024
